Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
07:00am, Thursday, 16'th Mar 2023
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
08:52pm, Saturday, 12'th Nov 2022
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference C
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
01:33pm, Wednesday, 09'th Nov 2022
BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
05:31pm, Wednesday, 02'nd Nov 2022
SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
07:00am, Friday, 09'th Sep 2022
SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment C
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
11:18am, Wednesday, 24'th Aug 2022
Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript
10:32pm, Wednesday, 10'th Aug 2022
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David McClung - CFO Confere
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 10'th Aug 2022
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
02:04pm, Thursday, 04'th Aug 2022
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
07:34pm, Wednesday, 11'th May 2022
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) CEO Peter Altman on Q1 2022 Results - Earnings Call Transcript
06:01pm, Wednesday, 11'th May 2022
BioCardia, Inc. (NASDAQ:BCDA ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President & Chief Executive Offi
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
12:03pm, Wednesday, 13'th Apr 2022
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump
09:32am, Tuesday, 12'th Apr 2022
The FDA has signed off BioCardia Inc's (NASDAQ: BCDA) Investigational New Drug (IND) application for BCDA-04 to initiate Phase 1/2 trial in adult patients recovering from Acute Respiratory Distress
Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open
09:25am, Tuesday, 12'th Apr 2022
Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News an
